Open Orphan, a Dublin-listed pharma services company, completed its merger with hVIVO, a clinical trial business that can accelerate drug and vaccine development, in a £13m deal. "The merger of Open Orphan and hVIVO is a key milestone in the execution of our strategy to become a larger-scale specialist pharma services business and in complementary segments where specialist skills and know-how command higher margins," Cathal Friel, Open Orphan CEO.